Comments to FDA: OTC Drug Products Share page: Docket Number: 00N-1256 This submission represents CHPA's detailed written comments as follow-up to the June meeting and is intended to complement the Association's oral presentation. Download Document Issues: OTC Medicines Rx-to-OTC Switch Related Posts Effectiveness of Phenylephrine as an Oral Decongestant Letter Comments on the Background Document on Propylparaben and Butylparaben in Skin-Applied Leave-On Products Jan 16, 2025 Comments Comments Regarding Enhancing Coverage of Preventative Services Under the Affordable Care Act Dec 26, 2024